Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$12.3b

Jazz Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:JAZZ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Mar 26SellUS$235,444Patricia CarrIndividual1,287US$182.94
03 Mar 26SellUS$1,118,613Bruce CozaddIndividual6,000US$187.84
27 Feb 26SellUS$213,243Patricia CarrIndividual1,117US$190.91
26 Feb 26SellUS$9,928,934Neena PatilIndividual51,809US$193.60
26 Feb 26SellUS$1,039,134Mary HendersonIndividual5,343US$194.49
26 Feb 26SellUS$243,222Patricia CarrIndividual1,253US$194.11
09 Dec 25SellUS$379,366Mary HendersonIndividual2,238US$169.51
05 Dec 25SellUS$27,378Patricia CarrIndividual160US$171.11
18 Nov 25SellUS$994,728Rick WinninghamIndividual5,500US$180.86
18 Nov 25SellUS$3,128,613Bruce CozaddIndividual17,283US$181.81
18 Nov 25SellUS$12,535Patricia CarrIndividual69US$181.66
18 Nov 25SellUS$130,925Bruce CozaddIndividual717US$182.60
12 May 25BuyUS$9,993,082Seamus MulliganIndividual101,621US$103.00

Insider Trading Volume

Insider Buying: JAZZ insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of JAZZ?
Owner TypeNumber of SharesOwnership Percentage
State or Government53,9780.0846%
Individual Insiders1,891,4382.97%
Institutions61,821,62196.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 66.8% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.61%
The Vanguard Group, Inc.
5,917,142US$1.2b0.17%0.01%
8.86%
BlackRock, Inc.
5,451,241US$1.1b-1.94%0.01%
4.33%
Capital Research and Management Company
2,666,602US$531.5m4.37%0.02%
4.26%
Dimensional Fund Advisors LP
2,623,303US$522.9m-7.52%0.06%
3.99%
LSV Asset Management
2,455,957US$489.5m-2.23%0.88%
2.99%
State Street Global Advisors, Inc.
1,837,793US$366.3m-1.61%0.01%
2.95%
Franklin Resources, Inc.
1,813,590US$361.5m164%0.1%
2.77%
EcoR1 Capital, LLC
1,706,469US$340.2m0%13.38%
2.72%
Fuller & Thaler Asset Management, Inc.
1,677,132US$334.3m3.14%1.03%
2.47%
Columbia Management Investment Advisers, LLC
1,521,090US$303.2m-17.7%0.06%
2.08%
Seamus Mulligan
1,277,727US$254.7m0%no data
2%
Millennium Management LLC
1,231,095US$245.4m357%0.15%
1.94%
Geode Capital Management, LLC
1,197,236US$238.6m0.1%0.01%
1.82%
BNY Asset Management
1,122,270US$223.7m159%0.04%
1.79%
Swedbank Robur Fonder AB
1,102,974US$219.9m2.69%0.14%
1.56%
Sofinnova Investment, Inc.
959,860US$191.3m63%8.94%
1.48%
AQR Capital Management, LLC
913,387US$182.1m25.1%0.1%
1.47%
JP Morgan Asset Management
905,665US$180.5m-47.1%0.02%
1.36%
Renaissance Technologies LLC
836,774US$166.8m-9.53%0.25%
1.24%
FMR LLC
763,668US$152.2m18.2%0.01%
1.05%
Pacer Advisors, Inc.
647,084US$129.0m19.8%0.33%
1.05%
BNPP Asset Management Holding
644,879US$128.5m15.7%0.14%
1.04%
GMT Capital Corp.
638,500US$127.3m-19.5%3.93%
1.01%
UBS Asset Management AG
621,275US$123.8m-0.46%0.01%
0.96%
Holocene Advisors, LP
589,735US$117.6m-2.54%0.24%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/16 06:06
End of Day Share Price 2026/04/16 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jazz Pharmaceuticals plc is covered by 47 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Brian SkorneyBaird
null nullBaird